Cagrilintide: difference between revisions
Diff·revision 5 → 6·07:25, 5 Oct 2024
Difference between revision 5 and revision 6 of Cagrilintide. 3 lines changed; the page grew by 304 bytes.
| Revision 5 — 02:12, 23 Sep 2024 IcodecIndra (talk) correct the dose ladder — the maintenance dose is not the maximum dose 2,102 bytes +215 | Revision 6 — 07:25, 5 Oct 2024 ComparisonCato (talk) British spelling per PP:MOS 2,406 bytes +304 | ||
|---|---|---|---|
| 18 | Cagrilintide adds acylation to that, giving the long half-life the earlier mealtime analogue lacked. It engages the calcitonin receptor as well as the amylin receptor complexes, and whether that broader engagement contributes to or detracts from the effect is not established.{{r|lau2021}} | 18 | Cagrilintide adds acylation to that, giving the long half-life the earlier mealtime analogue lacked. It engages the calcitonin receptor as well as the amylin receptor complexes, and whether that broader engagement contributes to or detracts from the effect is not established.{{r|lau2021}} |
| 19 | 19 | ||
| + | 20 | Because the receptor family is unrelated to the incretin receptors, no single molecule can engage both; this is why the semaglutide combination is a co-formulation rather than a unimolecular dual agonist. See [[Dual incretin agonist]].{{r|hay2015}} | |
| + | 21 | ||
| 20 | == References == | 22 | == References == |
| 21 | {{reflist}} | 23 | {{reflist}} |
| ⋮ | ⋮ | ||
| 26 | [[Category:Amylin analogues]] | 28 | [[Category:Amylin analogues]] |
| 27 | [[Category:Peptide drugs]] | 29 | [[Category:Peptide drugs]] |
| + | 30 | [[Category:Articles describing unapproved compounds]] | |
| 28 | 31 |